作者: Friederike Cordes , Dirk Foell , John Nik Ding , Georg Varga , Dominik Bettenworth
关键词:
摘要: In 2018, the pan-Janus kinase (JAK) inhibitor tofacitinib was launched for treatment of ulcerative colitis (UC). Although has proven efficacious in patients with active UC, it failed Crohn's disease (CD). This finding strongly hints at a different contribution JAK signaling both entities. Here, we review current knowledge on interplay between JAK/signal transducer and activator transcription (STAT) pathway inflammatory bowel diseases (IBD). particular, provide detailed overview differences similarities JAK/STAT-signaling UC CD, highlight impact JAK/STAT experimental models summarize published evidence immune cells IBD as well genetic association IBD. Finally, describe novel strategies targeting inhibition CD comment limitations challenges new drug class.